



**COMMONWEALTH OF KENTUCKY  
 CABINET FOR HEALTH AND FAMILY SERVICES  
 DEPARTMENT FOR MEDICAID SERVICES  
 PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.**  
 Thursday, April 18, 2024  
 1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
<p><a href="#">Click here to join the meeting</a></p> <p>Meeting ID: 236 450 276 153            Passcode: CqUVSX</p> <p><a href="#">Download Teams</a>   <a href="#">Join on the web</a></p>	<p>+1-858-252-2734 (US Toll)</p> <p>Phone Conference ID: 917 583 958#</p>

## AGENDA

- I. **Call to Order and Welcome**
- II. **Executive Session (upon request)**
- III. **Old Business**
  - a. Approval of November 2022 Meeting Minutes
  - b. Approval of March 2023 Meeting Minutes
  - c. Approval of May 2023 Meeting Minutes
  - d. Approval of September 2023 Meeting Minutes
  - e. Approval of November 2023 Meeting Minutes
  - f. Approval of January 2024 Meeting Minutes
- IV. **New Business**
  - a. New Products to Market to be Reviewed as Single Products:
    - i. Voquezna® (*Proton Pump Inhibitors*)
    - ii. Voquezna Dual & Triple Pak® (*H. Pylori Treatment*)
    - iii. Fabhalta® (*Non-PDL*)
    - iv. Jesduvroq® (*Erythropoiesis Stimulating Proteins*)
    - v. Wainua™ (*Non-PDL*)
    - vi. Agamree® (*Steroids, Oral*)
    - vii. Zilbrysq® (*Non-PDL*)
- V. **Therapeutic Classes with Recommended Changes**
  - a. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  - b. Antihyperuricemics
  - c. Erythropoiesis Stimulating Proteins
  - d. Steroids, Oral
  - e. Pancreatic Enzymes
  - f. Colony Stimulating Factors



**VI. Consent Agenda**

a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Narcotics, Long Acting</li> <li>• Narcotics, Short Acting</li> <li>• Narcotic Agonist/Antagonists</li> <li>• Narcotics, Fentanyl Buccal Products</li> <li>• Antimigraine Agents, Triptans</li> <li>• Antimigraine Agents, CGRP Inhibitors</li> <li>• Neuropathic Pain</li> <li>• Opiate Dependence Treatments</li> <li>• Skeletal Muscle Relaxants</li> <li>• Phosphate Binders</li> <li>• Sickle Cell Anemia Treatments</li> <li>• Thrombopoiesis Stimulating Proteins</li> <li>• Alpha-Glucosidase Inhibitors</li> <li>• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors</li> </ul>	<ul style="list-style-type: none"> <li>• Glucagon-Like Peptide (GLP-1) Receptor Agonists</li> <li>• Insulin &amp; Related Agents</li> <li>• Meglitinides</li> <li>• Metformins</li> <li>• Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors</li> <li>• Sulfonylureas</li> <li>• Thiazolidinediones (TZDs)</li> <li>• Androgenic Agents</li> <li>• Bone Resorption Suppression &amp; Related Agents</li> <li>• Glucagon Agents</li> <li>• Growth Hormones</li> <li>• Progestins for Cachexia</li> <li>• Uterine Disorder Treatments</li> </ul>
--	---

**VII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **July 18, 2024**
  - ii. **October 17, 2024**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request form located under the Committee Information tab at <https://kyportal.medimpact.com/medicaid-pt-committee/pt-committee>.